- Policy
- No budget set to compensate increasing Paxlovid AE reports
- by Lee, Jeong-Hwan Nov 7, 2022 06:05am
- It has been found that no government budget has been set to compensate for the adverse events that may occur after receiving COVID-19 treatments granted emergency use authorizations in Korea. Therefore, a claim has been raised that a supplementary budget needs to be set to review and provide damage relief from the use of EUA drugs that d
- Policy
- Strepto formulations negotiated at a rate of 20%
- by Lee, Tak-Sun Nov 4, 2022 05:39am
- The pharmaceutical industry has low drug prices, so if the recovery rate is more than 20%, there is no margin left Based on the results of the clinical re-evaluation of the anti-inflammatory enzyme drugs Streptokinase and Streptodornase, the NHIS and pharmaceutical companies, which have started negotiations to recover their salaries, are r
- Opinion
- [Reporter’s View] Reimb for SLGT-2i combo still in discussi
- by Eo, Yun-Ho Nov 4, 2022 05:39am
- The agenda has been in the last stages of review for 5 months. At this pace, discussions on expanding reimbursement of SGLT-2 inhibitors as combination therapy may again be passed on to the next year. The discussion on expanding reimbursement of SGLT-2 inhibitors as combination therapy has remained stagnant for a long time. After no progr
- Policy
- Government-Pharmaceutical Consultation on Acetaminophen
- by Lee, Jeong-Hwan Nov 4, 2022 05:39am
- The Ministry of Health and Welfare met with domestic and foreign pharmaceutical companies to cooperate to increase production and facilitate distribution of cold medicine Acetaminophen 650 mg, and actively promote necessary institutional support such as raising the price of drugs. Park Min-soo, the second vice minister of the Ministry of Heal
- Policy
- Reimb standards set for first RET-targeted Retevmo
- by Lee, Tak-Sun Nov 4, 2022 05:39am
- Reimbursement listing for Lilly’s ‘Retevmo cap(selpercatinib),’ the first RET-targeted anticancer therapy in Korea, is gaining speed after successfully setting reimbursement standards. As the drug is eligible for expedited listing in Korea as a treatment used for life-threatening conditions, its time to reimbursement listing is expect
- Policy
- The self-sufficiency of national essential drugs has begun
- by Lee, Hye-Kyung Nov 4, 2022 05:38am
- The selection of 11 candidate medicines that require the development of domestic manufacturing and quality evaluation technologies has been completed. The Ministry of Food and Drug Safety recently selected a total of 11 items (5 raw materials & 6 finished products) as the first stage of development candidates after deliberation by the Product Se
- Company
- Recobell can be prescribed at infertility centers
- by Eo, Yun-Ho Nov 3, 2022 05:54am
- The infertility treatment Recobell is available in general hospitals. According to related industries, Ferring Pharmaceutical's Recobell passed the Drug Committee of medical institutions with infertility centers such as Sinchon Severance Hospital, Bundang Seoul National University Hospital, and Bundang Cha Hospital. Along with the expansion o
- Downsizing underway at Sanofi... conducts voluntary ERP
- by Nov 3, 2022 05:54am
- Sanofi’s Korean subsidiaries Sanofi Aventis and Sanofi Pasteur are offering early retirement programs (ERPs) for their employees. It has been 2 years since the company offered the last ERP with the spin-off of its Sanofi Consumer Healthcare (CHC) business. According to industry sources on the 3rd, Sanofi-Aventis will accept voluntary r
- Product
- Imported Tylenol is sold at half the domestic price
- by Kim JiEun Nov 3, 2022 05:54am
- Tylenol is being sold on Online and SNS, has given up selling it because they could not get it at pharmacies. It is sold illegally through overseas direct purchases and parallel imports, and there is a need for the government to strengthen its crackdown. On the 1st, an informant informed Dailypharm that drugs such as Australian Tylenol are be
- Company
- Immuno-oncology drugs set out to conquer early stage cancer
- by Nov 3, 2022 05:54am
- The use of immuno-oncology drugs has advanced to the frontline of early-stage cancers. This is because data has demonstrated that the use of immuno-oncology drugs in the early stages increases the possibility of surgery and reduces the possibility of metastasis and recurrence. Following their use in the field of non-small cell lung cancer
